To get one, go to the subscriptions page. Biogen’s studies of its drug for a rare form of amyotrophic lateral sclerosis suggest the drug has a “treatment effect,” the Food and Drug ...

An FDA advisory panel voted for and against the clinical benefit of tofersen — Biogen’s investigational drug for amyotrophic lateral sclerosis, which failed to pass its primary endpoint in a ...

Medicare Advantage plans must cover Biogen’s (NASDAQ:BIIB) drug Qalsody for the treatment of ALS, according to a report. The U.S. Centers for Medicare & Medicaid Services has directed insurance ...

A Biogen drug that targets a rare form of ALS got partial support from a panel of US Food and Drug Administration advisers Wednesday, paving the way for a possible accelerated approval.

Despite the approval of Biogen Inc.’s Qalsody (tofersen) for treating amyotrophic lateral sclerosis (ALS), there are still hurdles for the drug to clear, including a confirmatory study and setting a ...

Biogen Inc. BIIB received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker’s proposed amyotrophic lateral sclerosis, or ALS ...

Biogen Inc.’s studies of its drug for a rare form of amyotrophic lateral sclerosis suggest the drug has a “treatment effect,” the Food and Drug Administration’s staff said in documents ...

An FDA advisory panel voted for and against the clinical benefit of tofersen — Biogen's investigational drug for amyotrophic lateral sclerosis, which failed to pass its primary endpoint in a ...